France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. (Reporting by GV De Clercq;Editing by Sudip Kar-Gupta ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...

Sanofi has become the latest big pharma company to boost manufacturing in the US with a hefty investment as the biopharma industry safeguards itself against the continued threat of pharma tariffs ...

We came across a bullish thesis on Sanofi (SNY) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on SNY. Sanofi (SNY)'s share was trading at $51.06 as ...

It's almost surreal to ride a drop pod down to the surface of one of EVE Online's tens of thousands of planets in the upcoming shooter tie-in, EVE Vanguard. I've flown by them hundreds of times in ...

PARIS, France — French pharmaceutical firm Sanofi said Wednesday it plans to invest at least $20 billion into its operations in the United States through 2030 to expand both research and ...

Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their American operations as President Donald Trump threatens to impose ...

Google has updated its iconic 'G' logo for the first time in almost a decade. While the new logo retains the 'G' in the familiar Product Sans format, it introduces significant changes to the ...

Sanofi plans to boost its U.S.-based research and development and manufacturing investments to at least $20 billon over the next five years. In a May 14 press release, the French multinational ...

Get ready to ring in the new year with Snoop Dogg. NBC and Peacock have set Snoop Dogg’s New Years Eve special, live from Miami on Dec. 31 at 10:30 pm ET/PT. The two-hour special promises “a ...

Investing.com -- Moody’s Ratings has upgraded the long-term issuer rating and senior unsecured ratings of Sanofi (NASDAQ:SNY) from A1 to Aa3. The outlook for the company has been revised from ...